Trending Now
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) Begins a Phase 3 Study...
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has started a Phase 3 study to assess the safety and efficacy of pitolisant. This drug could potentially...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Spectrum Therapeutics Inc. (NASDAQ:SPPI) Announced Q3 2020 Results And Poziotinib and...
Spectrum Therapeutics Inc. (NASDAQ:SPPI) has announced its financial results for the third quarter ended September 30, 2020.
FDA to review poziotinib NDA
Joe Turgeon the company's...
MAKE IT MODERN
LATEST REVIEWS
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) Begins a Phase 3 Study...
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) has started a Phase 3 study to assess the safety and efficacy of pitolisant. This drug could potentially...
MAKE IT MODERN
PERFORMANCE TRAINING
Clearmind Medicine Inc (CMND) briefly surges and here’s why
Clearmind Medicine Inc. (Nasdaq: CMND), a trailblazer in the field of psychedelic-derived therapeutics, is set to make a significant impact at the...
The US FDA Grants Fast Track Designation To IND – LB1148 Of Palisade Bio...
The US FDA granted fast track designation to Palisade Bio Inc (NASDAQ:PALI)’s LB1148 to treat adhesions following pelvic or abdominal surgery.
Inovio Pharmaceuticals Inc (NASDAQ:INO) Reports Favorable Data Of INO-4800 In NHP Studies: Demonstrates Protection...
Inovio Pharmaceuticals Inc (NASDAQ:INO) reported encouraging results in treating one of the difficult and most devastating cancers, GBM (glioblastoma multiforme). The company also achieved...
Investors Focus on Top Metaverse Plays as New Year Gets in Gear (U, EPAZ,...
The investing landscape for 2022 is uncertain, as we have seen over recent days. The year has started with selling driven by...
Cardlytics Inc (CDLX) surge is justified with its updated guidance
Cardlytics Inc (CDLX) opened today at $4.80, significantly higher than its previous close of $3.45. During the trading session, the bid price...
MAKE IT MODERN
